Federal Appellate Court Revives Tylenol Autism Claims
July 15, 2026
In its Opinion dated July 13, 2026, the United States Court of Appeals for the Second Circuit overturned dismissals of Plaintiffs’ failure-to-warn claims under state law relating to acetaminophen, the active ingredient in Tylenol and its generic equivalents. The Plaintiffs are children, parent[...]
Continue Reading
Safety Label Update For Capecitabine And Fluorouracil (5-FU)
March 28, 2026
The U.S. Food and Drug Administration (FDA) recently provided a communication to increase awareness of recent updates to the product labeling of capecitabine (Xeloda) and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency: all healthcare providers s[...]
Continue Reading
$41.5 Million Texas Settlement With Pfizer And Tris Pharma
January 10, 2026
In November 2023, the Texas Office of the Attorney General’s Civil Medicaid Fraud Division sued Pfizer, Inc., Tris Pharma, Inc. and Tris CEO Ketan Mehta for allegedly defrauding the Texas Medicaid program by providing adulterated pharmaceutical drugs to Texas children in violation of the Texas Med[...]
Continue Reading